Latest News
Highlights from ImmunoACT's Symposium on 30th April, at New Delhi on advances in CAR-T therapy for B-cell malignancies.
April 4, 2024
Immunoact has been recognized with the prestigious award for Outstanding Achievement in Immunotherapy at Precision Med India 2024 in New Delhi! This recognition is a testament to our dedication to advancing healthcare through innovative CAR-T cell therapies
April 2, 2024
Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
March 21, 2024
Nature
Listen to our Podcast : India’s breakthrough in cancer cure
March 20, 2024
Economic Times
NexCAR19 cancer therapy: Conceived at IIT Bombay, delivered in Tata Memorial Hospital
March 10, 2024
Mint News
Our Co-Founder & Head of Scientific Affairs, Atharva Karulkar, PhD highlighted our CAR-T platform which is now commercially approved for treating certain rare B-cell cancers, to representatives including Dr. V. K. Paul, Member NITI Ayog, and Bill Gates of the Bill & Melinda Gates Foundation
March 6, 2024
Our trailblazing NexCAR19, India’s first Market Approved CAR-T cell therapy, has bagged the #ETREPharmaAwards! A testament to our fruitful collaboration with IIT Bombay and Tata Memorial Centre
January 20, 2024
The Economics Times
Our work was recently highlighted by Ben Johnson and Nature Biotech's editorial team, in indigenising innovation to improve affordability & accessibility of CAR-T cell therapies as evidenced with the now commercially available NexCAR19 (Actalycabtagene autoleucel)
January 20, 2024
Nature Biotechnology
Sahyadri Hospitals, Pune have entered in to a partnership with ImmunoACT for administering CAR-T cell therapies, beginning with NexCAR19™ (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia
The Indian Express
January 16, 2024
P. D. Hinduja Hospital, Khar has partnered with ImmunoACT, to provide access to NexCAR19 (Actalycabtagene autoleucel) for its patients in a commercial setting.
January 19, 2024
Healthcareradius
Fortis Healthcare announces a collaboration with ImmunoACT, under this collaboration, Fortis Healthcare will provide this potentially life-saving autologous therapy at its extensive network of Bone Marrow Transplant centres in Delhi, Gurgaon, Noida, Mumbai, Bengaluru, and Mohali,
January 9, 2024
IIT Bombay Director Prof. Subhasis Chaudhuri and Prof. Rahul Purwar had a meeting with the Hon'ble President of India to invite her to campus and to dedicate the CAR-T cell therapy, developed at IIT Bombay, for Cancer treatment to the nation.
January 5, 2024
IIT Bombay
Max Healthcare announces a collaboration with ImmunoACT, to herald the start of its commercial CAR-T cell therapy program
December 5, 2023
The Economics Times
ImmunoACT gets CDSCO approval for India's first CAR-T cell therapy for blood cancer
October 13, 2023
The Economics Times
Breakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod
October 13, 2023
The Print
IIT-B startup ImmunoACT's “affordable” blood cancer therapy
gets regulatory approval - a first for India's CAR-T cell therapy
October 14, 2023
Times of India
CDSCO approves ImmunoACT’s CAR-T cell therapy
June 30, 2023
The Hindu
The Mexican government has partnered with ImmunoAct, an IIT Bombay-incubated company which is developing cutting-edge CAR -T cell
March 08, 2023
The Economics Times
Tata Memorial Centre and ImmunoACT have entered a strategic partnership with the vision to make India a leading center for the cutting-edge Cell and Gene based therapies
July 07, 2023
Indigenous CAR T Therapy to be soon available in India
September 22, 2022
Money Control
Gene therapy to cure leukemia at one-tenth global costs
June 12, 2022
Hindustan Times
IIT Bombay incubated company provides ray of hope for blood cancers in India
June 12, 2022
Moneycontrol
Laurus Labs to buy 26% in CAR T-cell therapy company
November 20, 2021
The Economic Times
Tata Memorial Hospital, IIT Bombay Collaborate for ‘First in India’ CAR-T Cell Therapy for Cancer Treatment
June 10, 2021
Gadgets 360: An NDTV initiative
Boost for Cancer Care in India: Tata Memorial Hospital, IIT Bombay Conduct First CAR-T Cell Therapy in Early Phase Pilot Clinical Trial
June 09, 2021
eHEALTH
India's first CAR-T cell therapy conducted at ACTREC, Tata Hospital in Mumbai
June 09, 2021
Outlook India
Tata Memorial Hospital conducts first CAR-T cell therapy
June 08, 2021
Biospectrum
Department of Biotechnology supported First CAR-T cell therapy conducted at ACTREC, Tata Hospital in Mumbai
June 08, 2021
DBT-BIRAC
Cutting edge cancer therapy developed in India. The Hindu, 08 June 2021
June 08, 2021
The Hindu